BIOYF.US Biosyent Inc.

Healthcare Pharmaceuticals USA Stocks
12.43 USD
Close of Nov 13, 2026
7.54 12.73
Market cap
USD 140M
P/E
20.0x
P/B
4.35x
ROE
22.7%
Dividend yield
1.27%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BIOYF.US undervalued?

Graham number
Price12.43
Graham value6.32
Premium96.8%

BIOYF.US trades 96.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biosyent Inc. fundamental analysis

No fundamental analysis for Biosyent Inc. yet.

Biosyent Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biosyent Inc.

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibe…

Full company profile